IART — Integra LifeSciences Holdings Income Statement

0.000.00%

Last trade - 00:00

HealthcareBalancedMid CapNeutral

Annual income statement for Integra LifeSciences Holdings, fiscal year end - December 31st, USD millions except per share, conversion factor applied.

	2020 December 31st	2021 December 31st	2022 December 31st	2023 December 31st	2024 December 31st
Period Length:	12 M	12 M	12 M	12 M	12 M
Source:	10-K	10-K	10-K	10-K	10-K
Standards:	USG	USG	USG	USG	USG
Status:	Final	Final	Final	Final	Final
Revenue
Total Revenue	1,372	1,542	1,558	1,542	1,611
Cost of Revenue
Gross Profit	886	977	982	973	955
Selling / General / Administrative Expenses
Research And Development
Depreciation and Amortization
Unusual Expense / Income
Total Operating Expenses	1,242	1,309	1,322	1,431	1,582
Operating Profit	130	233	235	111	28.1
Total Net Non Operating Interest Income / Expense
Other Net Non Operating Costs
Net Income Before Taxes	93.5	215	214	81.1	-18.2
Provision for Income Taxes
Net Income After Taxes	134	169	181	67.7	-6.94
Net Income Before Extraordinary Items
Net Income	134	169	181	67.7	-6.94
Income Available to Common Shareholders Excluding Extraordinary Items
Income Available to Common Shareholders Including Extraordinary Items
Diluted Net Income	134	169	181	67.7	-6.94
Diluted Weighted Average Shares
Basic EPS Including Extraordinary Items
Diluted EPS Including Extraordinary Items
Diluted EPS Excluding Extraordinary Items
Normalised Income Before Taxes
Normalised Income After Taxes
Normalised Income Available to Common Shareholders
Diluted Normalised EPS	2.25	2.39	2.75	2.52	1.21